2-(4-(2-furanoylamino)phenylamino)-3-pyrrolidino-1,4-naphthoquinone | 465547-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-(2-furanoylamino)phenylamino)-3-pyrrolidino-1,4-naphthoquinone
• 英文别名: N-[4-[(1,4-dioxo-3-pyrrolidin-1-ylnaphthalen-2-yl)amino]phenyl]furan-2-carboxamide
• CAS: 465547-54-0
• 化学式: C₂₅H₂₁N₃O₄
• 分子量: 427.459
• InChiKey: SDEJTZDDJBZMPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  四氢吡咯 、 糠酸（呋喃甲酸） 、 2-(4-aminophenylamino)-3-dichloro-1,4-naphthoquinone 生成 2-(4-(2-furanoylamino)phenylamino)-3-pyrrolidino-1,4-naphthoquinone
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Identification of compounds for the treatment or prevention of proliferative diseases
  申请人：——

  公开号：US20030232801A1

  公开（公告）日：2003-12-18

  The invention features compounds for the treatment of cancer and other proliferative diseases. These compounds were identified in screening assays that contact candidate compounds with a cell containing a nucleic acid that includes a HER2 regulatory element and a reporter sequence. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.

  这项发明涉及用于治疗癌症和其他增殖性疾病的化合物。这些化合物是在筛选测定中鉴定出来的，该筛选测定将候选化合物与含有包括HER2调节元件和报告基序的核酸的细胞接触。该发明还涉及与筛选测定中鉴定的化合物在结构上相关的化合物。最后，该发明涉及使用该发明的化合物治疗或预防增殖性疾病的方法。
• US6630589B1
  申请人：——

  公开号：US6630589B1

  公开（公告）日：2003-10-07
• [EN] IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF PROLIFERATIVE DISEASES<br/>[FR] IDENTIFICATION DE COMPOSES UTILES DANS LE TRAITEMENT OU LA PREVENTION DES MALADIES PROLIFERATIVES
  申请人：MESSAGE PHARMACEUTICALS INC

  公开号：WO2002077609A2

  公开（公告）日：2002-10-03

  The invention features screening assays for compounds that are potentially useful for treating or preventing a proliferative disease. The assays are based on contacting a candidate compound with a cell containing a nucleic acid including a HER2 regulatory element and a reporter sequence. In addition, the invention features compounds identified by the assays of the invention. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.